ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 63 filers reported holding ONCOMED PHARMACEUTICALS INC in Q2 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $118,000 | +7.3% | 12,831 | -10.0% | 0.00% | – |
Q4 2016 | $110,000 | -27.2% | 14,263 | +8.1% | 0.00% | -100.0% |
Q3 2016 | $151,000 | -63.1% | 13,193 | -60.3% | 0.00% | -50.0% |
Q2 2016 | $409,000 | +20.6% | 33,202 | -1.1% | 0.00% | +100.0% |
Q1 2016 | $339,000 | -56.6% | 33,569 | -3.2% | 0.00% | -66.7% |
Q4 2015 | $782,000 | +36.0% | 34,684 | +0.0% | 0.00% | 0.0% |
Q3 2015 | $575,000 | +133.7% | 34,678 | +217.2% | 0.00% | +200.0% |
Q2 2015 | $246,000 | +2.5% | 10,933 | +17.6% | 0.00% | 0.0% |
Q1 2015 | $240,000 | +14.8% | 9,293 | -3.1% | 0.00% | 0.0% |
Q4 2014 | $209,000 | +13.6% | 9,590 | -1.4% | 0.00% | 0.0% |
Q3 2014 | $184,000 | -17.9% | 9,724 | +1.2% | 0.00% | 0.0% |
Q2 2014 | $224,000 | +83.6% | 9,611 | +165.5% | 0.00% | 0.0% |
Q1 2014 | $122,000 | +14.0% | 3,620 | 0.0% | 0.00% | – |
Q4 2013 | $107,000 | -13.0% | 3,620 | -55.0% | 0.00% | -100.0% |
Q3 2013 | $123,000 | – | 8,052 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
Fondren Management LP | 25,136 | $26,000 | 0.02% |
Cannell & Co. | 281,983 | $293,000 | 0.01% |
APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |